(Q22252975)

https://api.crossref.org/works/10.1002%2F14651858.CD005593

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Donepezil for nursing home patients with dementia: a reinterpretation of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Economic evaluation of donepezil in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

AD2000: donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

Severe impairment battery. A neuropsychological test for severely demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

The Global Deterioration Scale for assessment of primary degenerative dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

A new rating scale for dementia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005593

7 January 2021

10.1002/14651858.CD005593

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

698580

698580

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference